Temasek-backed Transcenta mulls HK-China dual IPO listing


After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.
Source: Finance Asia
Read More: Temasek-backed Transcenta mulls HK-China dual IPO listing

Be the first to comment on "Temasek-backed Transcenta mulls HK-China dual IPO listing"

Leave a comment

Your email address will not be published.


*